Detection of a novel single nucleotide polymorphism of the human thiopurine s-methyltransferase gene in a Chinese individual.

A 62-year-old Chinese patient with recurrent pompholyx submitted his blood sample for pre-treatment thiopurine S-methyltransferase (TPMT) pharmacogenetic profiling, and it was found to harbour a novel single nucleotide polymorphism (SNP). The novel SNP, detected by mRNA sequencing, was a c.2T>C (g.11018T>C) transition in the start codon, causing a Met1Thr amino acid change. This finding was confirmed on a subsequent blood sample from the same patient by DNA sequencing. The patient was genotyped as TPMT*1/*29, sequentially named as such following the latest TPMT SNP (TPMT*1/*28) at the time of writing. The novel SNP is expected to result in complete lack of protein translation, similar to the impact exerted by TPMT*14, another start codon SNP of the TPMT gene.

[1]  C. Peterson,et al.  Characterization of a novel sequence variant, TPMT*28, in the human thiopurine methyltransferase gene , 2010, Pharmacogenetics and genomics.

[2]  J. Berg,et al.  Expressing thiopurine S-methyltransferase activity as units per litre of whole-blood overcomes misleading high results in patients with anaemia , 2010, Annals of clinical biochemistry.

[3]  J. Gisbert,et al.  Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain , 2009, European Journal of Human Genetics.

[4]  R. Leong,et al.  Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression , 2009, Internal medicine journal.

[5]  M. Hiratsuka,et al.  Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2 – *24) , 2008, Pharmacogenetics and genomics.

[6]  S. Sahasranaman,et al.  Clinical pharmacology and pharmacogenetics of thiopurines , 2008, European Journal of Clinical Pharmacology.

[7]  Y. Chan,et al.  Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore , 2008, European Journal of Clinical Pharmacology.

[8]  D. Gurwitz,et al.  clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe , 2006 .

[9]  M. Milek,et al.  Thiopurine S-Methyltransferase Pharmacogenetics: Genotype to Phenotype Correlation in the Slovenian Population , 2006, Pharmacology.

[10]  J. Bidwell,et al.  RT‐PCR permits simultaneous genotyping of thiopurine S‐methyltransferase allelic variants by multiplex induced heteroduplex analysis , 2004, Human mutation.

[11]  Michel Eichelbaum,et al.  Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. , 2004, Pharmacogenetics.

[12]  P. Söderkvist,et al.  Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. , 2004, Pharmacogenetics.

[13]  S. Cheung,et al.  Mistaken identity: misclassification of TPMT phenotype following blood transfusion. , 2003, European journal of gastroenterology & hepatology.

[14]  M. Schrappe,et al.  A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL , 2003, Leukemia.

[15]  L. Lennard.  Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions. , 1998, Therapeutic drug monitoring.

[16]  F. Henry,et al.  Cost effectiveness. , 1980, The Ohio State medical journal.